Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical and Radiographic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors.

Patrick J. Stiff, MD, William Bensinger, MD, Muneer H. Abidi, MD, Roger Gingrich, MD, Andrew S. Artz, MD, Wade Lovelace, Matthew Guo, PhD, Lyndah Dreiling, MD

Blood (2007) 110 (11): 477.

https://doi.org/10.1182/blood.V110.11.477.477

Published: 2007

Journal Articles

Final Results of a Large, Community Based Study Evaluating the Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in NHL and HD Patients.

Stephen J. Noga, MD, Janak Choksi, MD, Beiying Ding, PhD, Lyndah Dreiling, MD, Howard Ozer, MD

Blood (2006) 108 (11): 1153.

https://doi.org/10.1182/blood.V108.11.1153.1153

Published: 2006

Journal Articles

The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks.

Janice Gabrilove, MD, Ronald Paquette, MD, Roger M. Lyons, MD, Chaudhry Mushtaq, MD, Mikkael A. Sekeres, MD, Hung Lam, PhD, Lyndah Dreiling, PhD

Blood (2006) 108 (11): 2671.

https://doi.org/10.1182/blood.V108.11.2671.2671

Published: 2006

Journal Articles

Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.

Ghulam Mufti, Adam Bagg, Robert Hasserjian, Barbara Bain, David Kuter, Lyndah Dreiling, Janet Nichol

Blood (2006) 108 (11): 3982.

https://doi.org/10.1182/blood.V108.11.3982.3982

Published: 2006

Journal Articles

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Janice Gabrilove, Ron Paquette, Roger Lyons, Chaudhry Mushtaq, Mikkael Sekeres, Hung Lam, Lyndah Dreiling

Blood (2005) 106 (11): 2541.

https://doi.org/10.1182/blood.V106.11.2541.2541

Published: 2005

NARROW

Clinical and Radiographic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors.

Final Results of a Large, Community Based Study Evaluating the Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in NHL and HD Patients.

The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks.

Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Clinical and Radiographic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors.

Final Results of a Large, Community Based Study Evaluating the Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in NHL and HD Patients.

The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks.

Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only